Cargando…

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World Health Organization Classification of Tumors and Haematopoietic and Lymphoid Tissue. Ruxolitinib is an oral inhibitor of Janus kinase approved in the USA for the treatment of intermediate...

Descripción completa

Detalles Bibliográficos
Autor principal: Manduzio, Palma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315213/
https://www.ncbi.nlm.nih.gov/pubmed/28243106
http://dx.doi.org/10.2147/TCRM.S121683

Ejemplares similares